Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam
| Autor: | Hayk Ghukasyan, Thuy Le, Cecilia M. Shikuma, Nath Limpruttdham, Trieu Ly Vo, Lishomwa C. Ndhlovu, Louie Mar A Gangcuangco, Glen M. Chew, Thomas A. Premeaux, Robert H. Paul, Thao Vu Phuong, Dominic C. Chow, Van Vinh Chau Nguyen, Chathura Siriwardhana |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cyclopropanes
Efavirenz T cell Immunology Lipopolysaccharide Receptors HIV Infections Hepacivirus CD38 Emtricitabine medicine.disease_cause Neopterin chemistry.chemical_compound TIGIT Raltegravir Potassium Virology medicine Humans Coinfection business.industry virus diseases HLA-DR Antigens Immune dysregulation Raltegravir Hepatitis C Benzoxazines Infectious Diseases medicine.anatomical_structure Vietnam chemistry Alkynes business medicine.drug |
| Zdroj: | AIDS Res Hum Retroviruses |
| ISSN: | 1931-8405 0889-2229 |
| Popis: | The impact of HIV antiretroviral therapy (ART) on immune dysregulation associated with hepatitis C virus (HCV)/HIV coinfection is incompletely understood. We serially assessed monocyte activation (neopterin, sCD14, and sCD163) and T cell activation (HLA-DR, CD38) and immune exhaustion [program cell death protein 1 (PD1), TIGIT] in HIV/HCV-coinfected individuals who participated in a randomized trial performed in Vietnam designed to assess the hepatotoxicity of raltegravir (RAL)- versus efavirenz (EFV)-based therapy when used as first-time ART in combination with tenofovir disoproxil fumarate and emtricitabine. Baseline pre-ART values were compared with those from ART-naive HIV-monoinfected and HIV-seronegative individuals. Before ART, HIV/HCV-coinfected individuals had higher levels of neopterin, sCD14, and sCD163, and increased frequencies of CD38(+)HLA-DR(+), PD1(+), and TIGIT(+) CD4 and CD8 T cells compared with ART-naive HIV-monoinfected or HIV-seronegative individuals (all p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|